Oxiracetam – Powder, 50 grams

Oxiracetam differs from piracetam by a hydroxyl group at the 4-position of the shared pyrrolidinone ring.

This structural modification is studied for its influence on receptor-binding affinity and pharmacokinetic properties relative to the parent compound, within structure-activity relationship research mapping how substitutions on the racetam core scaffold alter target engagement at glutamatergic and cholinergic systems.

Comparative binding and functional assays against piracetam and other racetam-family compounds are the standard approach for characterising this relationship.

Patch-clamp electrophysiology in cultured neurons or brain slice preparations is the standard method for characterising compound effects on AMPA receptor-mediated excitatory postsynaptic currents (EPSCs), allowing researchers to quantify changes in current amplitude, kinetics, or desensitization properties following oxiracetam exposure. These functional electrophysiological readouts are typically paired with receptor-binding assays to distinguish direct receptor modulation from indirect effects on presynaptic glutamate release.

Because oxiracetam has been investigated for activity at both glutamatergic AMPA receptors and cholinergic high-affinity choline uptake, it serves as a research tool for studying potential crosstalk or convergent downstream effects between these two neurotransmitter systems on cognitive-relevant cellular endpoints (such as long-term potentiation models). Researchers isolating which pathway drives a given experimental outcome typically use selective antagonists for one system (e.g. an AMPA receptor antagonist) while measuring oxiracetam's effects on the other, to determine pathway dependence.